Literature DB >> 26215559

Correlation of tumor-infiltrating lymphocytes with bladder cancer recurrence in patients with solitary low-grade urothelial carcinoma.

Kristian Krpina1, Emina Babarović2, Nives Jonjić2.   

Abstract

The aim of the present study was to correlate tumor-infiltrating lymphocytes (TIL) with bladder cancer recurrence in patients with solitary low-grade non-muscle-invasive bladder cancer (NMIBC). We retrospectively identified from the institutional database 115 patients with solitary low-grade NMIBC after transurethral resection (TURBT) without adjuvant therapy and with complete follow-up, between 1996 and 2006. Tumor specimens were retrieved and tissue microarrays were constructed. Patients were divided in two groups: those who developed recurrent disease (n = 69) and those without recurrence (n = 46) during a follow-up period of a minimum of 5 years. Immunohistochemical staining for TIL with anti-CD3, CD4, CD8, CD20, CD56, CD68, and granzyme B (GrB) was performed. Student's t test, Mann-Whitney U test, as well as uni- and multivariate analyses were applied to compare the two patient groups. TIL were predominantly observed in cancer stroma. The number of CD3+ and CD8+ lymphocytes observed in the non-recurrent group of patients was lower than that in recurrent patients (p = 0.0001, p = 0.0002, respectively). Also, in uni- and multivariate analyses, levels of CD3+ TIL (OR = 5.4035; p = 0.0001 and OR = 5.8280; p = 0.0102) and CD8+ TIL (OR = 3.2857; p = 0.0036 and OR = 5.3257; p = 0.0092) showed prognostic value with regard to NMIBC recurrence. Our results suggest that CD3+ and CD8+ TIL are predictive of bladder cancer recurrence in patients with solitary low-grade NMIBC which might facilitate identification of patients with higher risk of recurrence. However, prospective validating studies have to confirm these results before immunohistochemical staining for CD3 and CD8 TIL can be included in the clinical workup of these patients.

Entities:  

Keywords:  Lymphocytes; Non-muscle-invasive bladder cancer; Recurrence; Treatment; Tumor-infiltrating

Mesh:

Substances:

Year:  2015        PMID: 26215559     DOI: 10.1007/s00428-015-1808-6

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  22 in total

Review 1.  Dual role of macrophages in tumor growth and angiogenesis.

Authors:  Chrystelle Lamagna; Michel Aurrand-Lions; Beat A Imhof
Journal:  J Leukoc Biol       Date:  2006-07-24       Impact factor: 4.962

2.  Prognostic and clinicopathological significance of survivin expression in bladder cancer patients: a meta-analysis.

Authors:  Shunzeng Lv; Ekaterina Turlova; Shigang Zhao; Huihui Kang; Mingzhi Han; Hong-Shuo Sun
Journal:  Tumour Biol       Date:  2013-10-08

3.  Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells.

Authors:  Esther Unitt; Simon M Rushbrook; Aileen Marshall; Susan Davies; Paul Gibbs; Lesley S Morris; Nicholas Coleman; Graeme J M Alexander
Journal:  Hepatology       Date:  2005-04       Impact factor: 17.425

4.  Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score.

Authors:  Georgios Gakis; Tilman Todenhöfer; Markus Renninger; David Schilling; Karl-Dietrich Sievert; Christian Schwentner; Arnulf Stenzl
Journal:  BJU Int       Date:  2011-04-20       Impact factor: 5.588

5.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

Authors:  Richard J Sylvester; Adrian P M van der Meijden; Willem Oosterlinck; J Alfred Witjes; Christian Bouffioux; Louis Denis; Donald W W Newling; Karlheinz Kurth
Journal:  Eur Urol       Date:  2006-01-17       Impact factor: 20.096

6.  Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines.

Authors:  Angelica Loskog; Christina Ninalga; Gabriella Paul-Wetterberg; Manuel de la Torre; Per-Uno Malmström; Thomas H Tötterman
Journal:  J Urol       Date:  2007-01       Impact factor: 7.450

Review 7.  Functional plasticity of macrophages: in situ reprogramming of tumor-associated macrophages.

Authors:  Robert D Stout; Stephanie K Watkins; Jill Suttles
Journal:  J Leukoc Biol       Date:  2009-07-15       Impact factor: 4.962

Review 8.  Molecular pathogenesis of bladder cancer.

Authors:  Margaret A Knowles
Journal:  Int J Clin Oncol       Date:  2008-08-15       Impact factor: 3.402

Review 9.  Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer.

Authors:  Chrysoula I Liakou; Sowmita Narayanan; Derek Ng Tang; Christopher J Logothetis; Padmanee Sharma
Journal:  Cancer Immun       Date:  2007-06-26

10.  Tumour infiltrating lymphocytes as an independent prognostic factor in transitional cell bladder cancer.

Authors:  P K Lipponen; M J Eskelinen; K Jauhiainen; E Harju; R Terho
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

View more
  17 in total

Review 1.  Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-11       Impact factor: 3.875

2.  Prognostic impact of tumor infiltrating lymphocytes in bladder urothelial carcinoma.

Authors:  Hyung Suk Kim; Ja Hyeon Ku
Journal:  Transl Androl Urol       Date:  2019-07

3.  Bladder carcinomas in patients with neurogenic bladder and urinary schistosomiasis: are they the same tumors?

Authors:  Fabiana Cancrini; Floriane Michel; Olivier Cussenot; Hussa Alshehhi; Eva Comperat; Véronique Phé
Journal:  World J Urol       Date:  2022-01-29       Impact factor: 3.661

4.  The Tumor Microenvironment of Bladder Cancer.

Authors:  Ken Hatogai; Randy F Sweis
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 5.  Competitive glucose metabolism as a target to boost bladder cancer immunotherapy.

Authors:  Julieta Afonso; Lúcio L Santos; Adhemar Longatto-Filho; Fátima Baltazar
Journal:  Nat Rev Urol       Date:  2020-01-17       Impact factor: 14.432

6.  Clinical significance of T-bet, GATA-3, and Bcl-6 transcription factor expression in bladder carcinoma.

Authors:  Islem Ben Bahria-Sediki; Nadhir Yousfi; Catherine Paul; Mohamed Chebil; Mohamed Cherif; Rachida Zermani; Amel Ben Ammar El Gaaied; Ali Bettaieb
Journal:  J Transl Med       Date:  2016-05-30       Impact factor: 5.531

Review 7.  HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer.

Authors:  Tristan A Barnes; Eitan Amir
Journal:  Br J Cancer       Date:  2017-07-13       Impact factor: 7.640

8.  Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping.

Authors:  Moritz Jesinghaus; Katja Steiger; Julia Slotta-Huspenina; Enken Drecoll; Nicole Pfarr; Petra Meyer; Björn Konukiewitz; Marcus Bettstetter; Kathrin Wieczorek; Katja Ott; Markus Feith; Rupert Langer; Wilko Weichert; Katja Specht; Melanie Boxberg
Journal:  Oncotarget       Date:  2017-07-18

9.  Intratumoral CD56bright natural killer cells are associated with improved survival in bladder cancer.

Authors:  Neelam Mukherjee; Niannian Ji; Vincent Hurez; Tyler J Curiel; Maureen O Montgomery; Andrew J Braun; Marlo Nicolas; Marcela Aguilera; Dharam Kaushik; Qianqian Liu; Jianhua Ruan; Kerri A Kendrick; Robert S Svatek
Journal:  Oncotarget       Date:  2018-11-23

10.  Tumor-infiltrating plasma cells are the promising prognosis marker for esophageal squamous cell carcinoma.

Authors:  Chengyun Yao; Hongliang Yu; Guoren Zhou; Jianhua Xu; Dayong Gu; Li Yin; Xia He; Hongping Xia
Journal:  Esophagus       Date:  2021-03-10       Impact factor: 4.230

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.